WASHINGTON — The White House has been quick to claim credit for numerous drug companies’ decisions to back off planned price hikes for the remainder of 2018.

But such crowing from the Trump administration has not sat well with Democrats, who this week unveiled a pair of bills aimed at lowering prescription drug costs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This is good commonsense legislation that should pass unanimously. The GOP leaders will NOT allow this Bill to come to the floor for a vote because they are beholden to BIG PHARMA! THINK ABOUT THAT AMERICA!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy